BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27379812)

  • 1. Clinical use of checkpoint inhibition in kidney cancer.
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):427-9. PubMed ID: 27379812
    [No Abstract]   [Full Text] [Related]  

  • 2. The science of checkpoint inhibition in kidney cancer.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):214-7. PubMed ID: 27166601
    [No Abstract]   [Full Text] [Related]  

  • 3. Checkpoint inhibitors in breast cancer: hype or promise?
    McArthur HL
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune Checkpoint Therapy in Renal Cell Carcinoma.
    Lee CH; Motzer RJ
    Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Therapy in Melanoma.
    Callahan MK
    Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
    Buti S; Bersanelli M
    Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
    [No Abstract]   [Full Text] [Related]  

  • 7. Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?
    El Rassy E; Assi T; Kattan J
    Future Oncol; 2017 Feb; 13(5):381-383. PubMed ID: 27884060
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune Checkpoint Therapies in Prostate Cancer.
    Goswami S; Aparicio A; Subudhi SK
    Cancer J; 2016; 22(2):117-20. PubMed ID: 27111907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
    Campbell MT; Siefker-Radtke AO; Gao J
    Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are virus-induced cancers more sensitive to checkpoint inhibitors?
    Kanaan H; Kourie HR; Awada AH
    Future Oncol; 2016 Dec; 12(23):2665-2668. PubMed ID: 27513334
    [No Abstract]   [Full Text] [Related]  

  • 11. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
    Pal SK; Hu A; Chang M; Figlin RA
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.
    Ring KL; Pakish J; Jazaeri AA
    Cancer J; 2016; 22(2):101-7. PubMed ID: 27111905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Therapy in Head and Neck Cancers.
    Msaouel P; Massarelli E
    Cancer J; 2016; 22(2):108-16. PubMed ID: 27111906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
    Monteiro ID; Califano R; Mountzios G; de Mello RA
    Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
    Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
    Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.